VistaGen Therapeutics, Inc.
12
2
3
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
16.7%
2 terminated/withdrawn out of 12 trials
71.4%
-15.1% vs industry average
42%
5 trials in Phase 3/4
100%
5 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4)
Role: lead
A Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder
Role: lead
PH94B in the Treatment of Adjustment Disorder With Anxiety
Role: lead
Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-3)
Role: lead
PH94B Nasal Spray for Anxiety Induced by a Public Speaking Challenge - 2
Role: lead
Open-label Safety Trial of PH94B in Social Anxiety Disorder (SAD)
Role: lead
PH94B Nasal Spray for Anxiety Induced by a Public Speaking Challenge
Role: lead
AV-101 Alone and in Combination With Probenecid in Healthy Subjects
Role: lead
Electrophysiological Biomarkers of AV-101
Role: collaborator
AV-101 (L-4-chlorokynurenine) in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesia
Role: lead
AV-101 as Adjunct Antidepressant Therapy in Patients With Major Depression
Role: lead
Safety, Tolerability and Pharmacokinetics of Multiple Doses of AV-101 in Healthy Volunteers
Role: lead
All 12 trials loaded